Novel Interventions in Criminal Justice Populations Division
Currently the Division is the lead site of five year multi-site
effectiveness study to determine whether the addition of a monthly
injection of depot naltrexone to treatment as usual (TAU) will
significantly improve outcome in offenders with a history of opioid
addiction compared to TAU alone. Three-hundred and eight (308)
participants were randomized to either treatment as usual in community
programs or monthly injections of depot naltrexone for six months with
treatment as usual in community programs. The effectiveness of depot
naltrexone has never been studied in opioid dependent offenders. All
offender subjects will be evaluated at baseline, while in treatment, and
at 6, 12 and 18‑month post-entry time points. The primary study
outcomes are retention in treatment, drug use, re-arrests, psychosocial
and medical/psychiatric functioning, and economic costs and benefit
costs of naltrexone. The Division is in the final year of the trial.
Twelve (12) and 18 month follow-up visits are still underway. The study
sites are the University of Pennsylvania in Philadelphia, The Social
Research Center of Friends Research Institute in Baltimore, Virginia
Commonwealth University in Richmond, New York University in New York,
Columbia University in New York, and Brown University in Providence.
For additional information on this trial, please call 215-746-7296.